Different treatments on efficacy, islet function and oxidative stress after short-term intensive insulin therapy in patients with newly diagnosed type 2 diabetes mellitus

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17011488

Enrollment

Unknown

Registered

2017-05-25

Start date

2015-11-11

Completion date

Unknown

Last updated

2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Newly diagnosed type 2 diabetes mellitus

Interventions

Metformin :Metformin 500mg tid

saxagliptin :Saxagliptin 5mg qd

intensive insulin therapy:lispro insulin

Eligibility

Sex/Gender

All

Age

28 Years to 69 Years

Inclusion criteria

Inclusion criteria: 1. new diagnostic T2DM (WHO 1999 standard); 2. aged 25-70 years old; 3. FPG> 11.1mmol/L or glycosylated hemoglobin (HbA1c)> 9%; 4. never received hypoglycemic drug therapy.

Exclusion criteria

Exclusion criteria: 1. type 1 or other types of diabetes; 2. acute diabetic complications (including diabetic ketoacidosis, hypertonic status of diabetes); 3. liver and kidney dysfunction or cardiopulmonary dysfunction history (ALT 2.5 times; serum creatinine concentration over the reference Range; NYHA cardiac function grade 3 or above); 4. acute infection, malignancy, pregnancy or within six months of planned pregnancy; 5. have any hypoglycemic or insulin treatment history; 6. Researchers determine poor compliance and are not suitable for participants.

Design outcomes

Primary

Measure	Time frame
Glycated hemoglobin;Blood glucose;C-peptide;Glucagon;Proinsulin;Malondialdehyde;Superoxide dismutase;	—

Countries

China

Contacts

Public ContactYing Zhang

The Third Affiliated Hospital of Guangzhou Medical University

zhangying30412@163.com+86 18928916685

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026